SynAct Pharma is a clinical stage biotechnology company developing new innovative medicines with the ability to induce resolution of inflammation. The treatment potential of our compounds is not only to induce reduction in inflammation, but to activate pathways and induce distinct cell phenotypes thereby promoting the clearance of inflammatory cells and a return to new inflammatory homeostatic setpoint.
This novel approach has the potential to be a complementary, or potentially superior, strategy to traditional treatment options, not only because it has the potential to regulate the inflammation and thereby restoring tissue and organ functionality but induce its treatments actions without suppressing the immune system.
The company addresses the concept of resolution in inflammation in two major development paths with the potential improving the life of the patient and creating major value for physicians and society as it addressed a unmet medical need for patient friendly, safe once daily oral treatment that can given as add on existing treatment with the potential to reduce the use of less well tolerated and potentially expensive treatment option and to facility faster recovery.
In inflammatory and autoimmune diseases where the companies lead compound resomelagon (AP1189) is in phase 2b development in newly diagnosed rheumatoid arthritis patients with high disease activity including signs of systemic inflammation. These patients present with poor prognosis factors, i.e. high risk of early irreversible damage to the joints and will often need cotreatment with glucocorticoids, to induce disease control. Consequently, these patients would have the specific benefit of a new treatment option as the one SynAct currently has in development
In severe viral infections, an inappropriate hyper inflammatory response is triggered in the patients. If not controlled, as demonstrated during the pandemic, this hyperinflammatory response can have devastating consequences. SynAct pharma has an ongoing Phase 2 development program demonstrated that induction of resolution of inflammation by treatment with resomelagon (P1189) has the potential to reduce disease activity and facilitate faster recovery. This treatment approach can be approached in hospitalized patients as well as in a prehospital setting to avoid further development of the disease. Currently, the treatment approach is evaluated in a Phase 2 study in Dengue fever.
The company has a broad portfolio of both oral small molecules and injectable peptide melanocortin agonists aimed at inducing resolution of inflammation. Our lead drug resomelagon (AP1189), is a first in class biased melanocortin type 1 and 3 receptor agonist developed as a once-daily oral tablet. TXP-11 is peptide melanocortin receptor agonist in preclinical development that is excepted to the ready to phase 1 clinicl development by the end of 2025. The compound is developed for intravenous infusion to preserve organ function in high risk hospitalized patients.
Vision
To lead the development of inflammation resolution therapeutics, a new approach to treating inflammatory diseases that does not suppress the immune system and that enables patients to achieve immune balance and live beyond their inflammation.
Mission
SynAct seeks to develop resomelagon (AP1189) and its peptide melanocortin agonists through proof-of-concept Phase 2 clinical studies. SynAct will seek to establish partnerships and collaborations with like-minded parties for Phase 3 studies and beyond.
